Loading
NASDAQHealthcareMedical - Devices
Latest quote
$4.92
+$0.07 · +1.44%
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Latest quote
$4.92
+$0.07 · +1.44%
Regular session · ET · Market data may be delayed.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Day range
Current $4.92
52-week range
Current $4.92
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
29
Expensive
Sentiment
51
Mixed
Risk
96
Extreme Risk
Momentum
33
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Day range
Current $4.92
52-week range
Current $4.92
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 301.65K USD | 168.72K USD | 110.75K USD | 1.32M USD | 144.07K USD |
| Cost of goods sold | 61.37K USD | 36.59K USD | 25.69K USD | 363.21K USD | 21.44K USD |
| Gross profit | 240.27K USD | 132.13K USD | 85.06K USD | 958.15K USD | 122.62K USD |
| Research and development | 1.08M USD | 1.19M USD | 1.92M USD | 511K USD | 139K USD |
| Selling, general, and administrative | 7.55M USD | 6.7M USD | 3.86M USD | 2.79M USD | 6.14M USD |
| Operating expenses | 8.63M USD | 7.89M USD | 5.78M USD | 2.79M USD | 6.14M USD |
| Interest income | 8.24K USD | 3.19K USD | — | — | — |
| Interest expense | — | — | 38.84K USD | 59.38K USD | 82.32K USD |
| Depreciation and amortization | 21.54K USD | 15.11K USD | 4.25K USD | 5.72K USD | 537 USD |
| Operating income | −8.39M USD | −7.75M USD | −5.7M USD | −1.83M USD | −6.02M USD |
| Net income | −8.22M USD | −7.61M USD | −4.65M USD | −1.7M USD | −6.08M USD |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 31, 2026 | 1:30 | — | — |
Effective Aug 31, 2026
1:30
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
